Xencor Inc. Stock
Price
Target price
?
?
-0.790%
-0.1
-0.790%
€26.59
07:37 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
The price for the Xencor Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.790%).
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 26 € there is potential for a 108.0% increase which would mean more than doubling the current price of 12.5 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -0.790% | 15.385% | 21.212% | -37.173% | -47.368% | -56.204% | -62.264% |
| Ironwood Pharmaceuticals | 27.560% | -7.971% | -3.053% | -66.043% | -69.762% | -88.675% | -84.790% |
| Novocure Ltd | -2.790% | -5.927% | -7.378% | -25.586% | -61.848% | -85.007% | -88.477% |
| Iovance Biotherapeutics Inc. | -0.080% | -11.760% | -11.088% | -83.536% | -75.337% | -81.973% | -94.560% |
Comments
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP
Xencor Reports First Quarter 2025 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the
